|
|
Vaccine Detail
|
Bcr-Abl (b3a2)-Derived Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Bcr-Abl (b3a2)-Derived Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: bcr-abl p210-b3a2 breakpoint-derived pentapeptide (NCT00466726)
- Immunization Route: subcutaneous injection
- Description: The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. (NCT00466726)
|
| Host Response |
|
|
| References |
NCT00466726: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206) [https://clinicaltrials.gov/study/NCT00466726]
|
|
